A Study Evaluating Pertuzumab (Perjeta) Combined With Trastuzumab (Herceptin) and Standard Anthracycline-based Chemotherapy in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Locally Advanced, Inflammatory, or Early-stage Breast Cancer

NCT02132949 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

401

Enrollment

INDUSTRY

Sponsor class

Conditions

Breast Cancer

Interventions

DRUG: 5-Fluorouracil
DRUG: Cyclophosphamide
DRUG: Docetaxel
DRUG: Doxorubicin
DRUG: Epirubicin
DRUG: Paclitaxel
DRUG: Pertuzumab
DRUG: Trastuzumab

Sponsor

Hoffmann-La Roche